TY - JOUR T1 - Ten years of human papillomavirus vaccination. From dermatology to oncology via infectology JO - Anales de Pediatría (English Edition) T2 - AU - Moraga-Llop,Fernando A. SN - 23412879 M3 - 10.1016/j.anpede.2017.12.004 DO - 10.1016/j.anpede.2017.12.004 UR - https://analesdepediatria.org/en-ten-years-human-papillomavirus-vaccination--articulo-S2341287918300590 AB - Human papillomavirus (HPV) was first identified in dermatology, and it was subsequently demonstrated that is was required for the development of uterine cervical cancer and other tumours, after a persistent infection by any of its oncogenic genotypes. Ten years ago, the most common infections and cancers associated with HPV could be prevented by immunization with 2 vaccines, one bivalent, and another tetravalent, and having just marketed a nonavalent one. During the period 2007–2008, the HPV vaccine was included in the Autonomous Communities vaccination calendar, and it is the second vaccine, after that of Hepatitis B, that prevents cancer. In these 10 years that these vaccines have been available the knowledge has progressed and there have been significant advances in vaccination strategies, as well as in the indications and recommendations. These include, lowering the age in the vaccination schedule, prescribing of 2 doses at 9 years and at 13–14 years, systematic vaccination of the male in some countries, immunization of the woman after adolescence, implementation of vaccination programmes in developed countries, prevention of other cancers, recommendations for vaccinations for populations at high risk of HPV infection, scientific evidence on the impact and effectiveness of vaccination, and confirmation of the safety of these vaccines, with more than 270 million doses administered, as has already been observed in clinical trials. The role of health professionals is essential to achieve and maintain high vaccine coverage. ER -